Our leaders

Determined to solve the intractable

Leadership Team

Curve Graphic

Jeff Albers

Executive Chairman of the Board of Directors

Jeff Albers
Executive Chairman of the Board of Directors

Jeff has more than 25 years of experience working in the biopharmaceutical industry and bringing important new medicines to patients with cancer and rare diseases. From 2014 to 2022, he served as Chief Executive Officer of Blueprint Medicines, where he led the research-stage company through an initial public offering and evolved it into a leading precision medicine company with a global, fully integrated business, including two FDA-approved therapies and a rapidly advancing pipeline. Jeff previously served as President of Algeta, where he oversaw the successful commercial launch of a targeted cancer therapy prior to the company’s acquisition by Bayer. Prior to Algeta, he held senior commercial and corporate development positions at Genzyme (now a division of Sanofi), including vice president of the U.S. hematology and oncology business unit. Earlier in his career, Jeff was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. He currently serves on the board of directors at Magenta Therapeutics and Kymera Therapeutics and is on the board of advisors for Life Sciences Cares. He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.

1

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.

Curve Graphic

Percy Carter, MBA, Ph.D.

Chief Scientific Officer

Percy Carter, MBA, Ph.D.
Chief Scientific Officer

Percy brings more than 20 years of global leadership in pharmaceutical companies and industry experience. Prior to joining Blueprint Medicines, he served as Chief Scientific Officer at FibroGen, Inc. He previously served as Global Head of Discovery Sciences at Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, where he led more than 700 employees comprising several key research and discovery functions, and drove the synthetic discovery strategy in collaboration with partners across various therapeutic areas. From August 2001 to May 2019, Percy held roles of increasing responsibility in drug discovery, covering all therapeutic areas, drug platforms and stages of discovery at Bristol-Myers Squibb (BMS), including serving as Senior Vice President and Head of Discovery. Prior to his experience at BMS, he was Senior Research Scientist in Chemical and Physical Sciences at DuPont Pharmaceuticals, until it was acquired by BMS in 2001. Percy is an inventor or co-inventor on more than 28 U.S. patents, and has authored or co-authored numerous peer-reviewed publications. He received an A.B. in Chemistry from Dartmouth College and a Ph.D. in Organic Chemistry from Harvard University. In addition, he received an MBA from Massachusetts Institute of Technology.

2

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.

Curve Graphic

Debbie Durso-Bumpus

Chief People Officer

Debbie Durso-Bumpus
Chief People Officer

Debbie is an accomplished human resources executive with a focus on providing strategic direction to companies on people matters, managing rapid growth and creating and maintaining high performance cultures. Most recently, Debbie served as the interim head of human resources for Cubist Pharmaceuticals, Inc., where she was appointed to lead the post-merger human resource integration following the acquisition of Cubist by Merck.  Prior to this role, she was the global senior director for talent management and organizational development at Cubist, where she was primarily responsible for building talent and leadership strength and depth while managing change on a global scale to create a cohesive and highly differentiated culture. Prior to Cubist, Debbie served as the North American manager of talent acquisition and workforce planning at Holcim, Inc., in Waltham, MA. She serves as a member of the board of directors for the Massachusetts Biotechnology Education Foundation, a nonprofit organization committed to supporting science and biotechnology education in Massachusetts through school programs, workforce training and lifelong learning. Debbie earned a B.S. in business management from Bentley University.

3

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.

Curve Graphic

Kate Haviland

Chief Executive Officer

Kate Haviland
Chief Executive Officer

Kate brings an impressive breadth of experience and leadership within the biopharmaceutical industry, as well as a substantial background in business development, commercial and strategic planning, and program management. Since April 2022, Kate has served as Chief Executive Officer of Blueprint Medicines. Previously, she served as Chief Operating Officer from January 2019 to April 2022, and as Chief Business Officer from January 2016 to January 2019. Over this time, she served as the founding chair of the portfolio management team, formed and executed business development strategy, drove global capital investment plans, and played a key role in capital market financings. In addition, she worked to drive the transformative growth of the company and support its evolution into a fully integrated business by developing and providing ongoing management of critical functions, including portfolio strategy, corporate development, commercial strategy, international, technical operations, corporate affairs, and information systems. Prior to joining Blueprint Medicines, Kate held leadership roles focused on building emerging, high-growth companies and advancing the development of innovative therapies in oncology and rare diseases as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals, Head of Commercial Development at Sarepta Therapeutics, Executive Director of Commercial Development at PTC Therapeutics, and roles in both corporate development and project management at Genzyme. She holds a B.A. from Wesleyan University with a double major in Biochemistry/Molecular Biology and Economics and an M.B.A. from Harvard Business School. Kate currently serves as chair of the board of directors at Fulcrum Therapeutics and is a member of the audit and compensation committees.

4

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.

Curve Graphic

Becker Hewes, M.D.

Chief Medical Officer

Becker Hewes, M.D.
Chief Medical Officer

Becker brings 20 years of industry and clinical experience in oncology and hematology, including achieving the approval of three tyrosine kinase inhibitors. Previously, he served as Blueprint Medicines’ Senior Vice President, Clinical Development from May 2020 to January 2021. Prior to joining Blueprint Medicines, Becker served as Chief Medical Officer of Repertoire Immune Medicines (formerly Torque Therapeutics) from February 2017 to May 2020, where he built Repertoire’s multidisciplinary clinical and biomarker team and advanced its lead immuno-oncology programs into clinical development. From June 2013 to February 2017, Becker served as Executive Director of Translational Clinical Oncology at the Novartis Institutes for BioMedical Research where he led clinical development and translational medicine efforts for multiple early-stage oncology programs through clinical proof-of-concept, including Kisqali® (ribociclib), a targeted therapy approved to treat breast cancer, and other programs combining novel therapies. Prior to that, he held roles of increasing responsibility related to clinical development in oncology and hematology within AstraZeneca PLC, Genzyme Corporation and Wyeth Pharmaceuticals, including leading registration programs for Bosulif® (bosutinib) and Torisel® (temsirolimus) for chronic myelogenous leukemia and mantle cell lymphoma, respectively. Before joining industry, he conducted immuno-oncology research at the Emory Vaccine Center while treating patients as a pediatric oncologist at Children’s Healthcare of Atlanta. Becker holds an M.D. from the Georgetown University School of Medicine and a B.S. from Vanderbilt University.

5

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.

Curve Graphic

Helen Ho, Ph.D.

Chief Business Officer

Helen Ho, Ph.D.
Chief Business Officer

Helen brings more than 15 years of pharmaceutical and biotechnology industry experience with a strong track record in business development, corporate growth strategy and operations. She joined Blueprint Medicines in April 2018, most recently serving as Senior Vice President, Corporate Development accountable for business development, alliance management and new product planning. In her present role, she is responsible for driving the company’s corporate strategy, leading Business Development and Portfolio Strategy & Program Management. Prior to joining Blueprint Medicines, Helen served as Vice President, Head of Corporate Development at TCR2 Therapeutics. She led portfolio strategy, business development and investor & public relations which culminated in closing of $125M Series B crossover financing. Prior to TCR2 Therapeutics, Helen was the Director, Business Development & Operations at Agios Pharmaceuticals where she played a broad role in company building having led the business development licensing function, supported company’s IPO and building of its Rare Genetic Disorders and Immuno-Oncology franchises. Previously, Helen was a management consultant at L.E.K Consulting leading projects from both Boston and Shanghai offices. Helen holds a Ph.D. in Cell Biology from Yale University and B.S. in Biochemistry from University of California, Los Angeles.

6

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.

Curve Graphic

Philina Lee, Ph.D.

Chief Commercial Officer

Philina Lee, Ph.D.
Chief Commercial Officer

Philina brings more than 15 years of biopharmaceutical industry leadership experience, with a strong track record of product commercialization and successfully building high growth organizations while fostering a strong company culture. Since April 2022, Philina has served as Chief Commercial Officer of Blueprint Medicines. She joined Blueprint Medicines in August 2014 as Senior Director, New Product Strategy and Development and subsequently held multiple commercial roles with responsibility for strategy, operations, patient services, marketing and the precision medicine field team. During her tenure, she has been instrumental in building the company’s portfolio from research-stage onwards, laying the groundwork for the commercial strategy that is driving the successful launches of AYVAKIT® (avapritinib) and GAVRETO® (pralsetinib). From January 2021 to April 2022, she served as Senior Vice President, Head of Portfolio Strategy and Program Management, where she was responsible for providing strategic and operational leadership across the company’s portfolio. Previously, Philina held product strategy and marketing roles of increasing responsibility at Algeta, Sanofi and Genzyme. She serves on the board of Fusion Pharmaceuticals, as a member of both the Nomination and Governance committee and Research and Development committee. Philina earned a B.S. in Biochemistry from the University of Alberta, and a Ph.D. in Cell Biology from the Massachusetts Institute of Technology.

8

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.

Curve Graphic

Tracey L. McCain, Esq.

Executive Vice President, Chief Legal and Compliance Officer

Tracey L. McCain, Esq.
Executive Vice President, Chief Legal and Compliance Officer

Tracey is an experienced legal professional with over 25 years of legal, management and transactional experience in the biopharmaceutical industry.  Most recently, Tracey served as senior vice president and head of legal for Sanofi Genzyme, a global business unit of Sanofi, as well as a member of Sanofi Genzyme’s executive leadership team and as a member of the leadership team for Sanofi’s global legal department.  Prior to that, Tracey served as Genzyme’s general counsel after it was acquired by Sanofi in 2011.  In her capacity as Genzyme’s general counsel, Tracey was responsible for all aspects of its legal department in the United States and throughout Europe, including general corporate, commercial and intellectual property matters, and support of business development initiatives.  Prior to Genzyme’s acquisition, Tracey was also responsible for managing the securities and employment law teams and support of non-patent litigation. Before Genzyme, Tracey was an associate at the law firm Palmer & Dodge LLP. She currently sits on the boards of directors at Kiniksa Pharmaceuticals and ImmunoGen, as well as the board of trustees at Dana Farber Cancer Institute. Tracey received her B.A. in political science from the University of Pennsylvania and her J.D. from Columbia University School of Law.

9

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.

Curve Graphic

Fouad Namouni, M.D.

President, Research & Development

Fouad Namouni, M.D.
President, Research & Development

Fouad brings more than 20 years of oncology and cancer immunotherapy drug development expertise, as well as clinical experience as a pediatric oncologist. Prior to joining Blueprint Medicines, Fouad served in leadership roles at Bristol-Myers Squibb (BMS) since 1999, including as the global development lead for the company’s practice-changing cancer immunotherapy franchise. Most recently, he served as Senior Vice President and Head of Oncology Development from August 2016 to April 2020, with responsibility for driving product development plans from early-stage clinical development through commercialization across a portfolio of nearly 30 drug candidates. Previously, he served as Head of Global Medical Affairs overseeing 1,700 employees worldwide from September 2015 to September 2017, and he served as Head of Development at BMS for Opdivo® (nivolumab) and Yervoy® (ipilimumab), immunotherapy medications used in the treatment of cancer, from January 2011 to September 2015. Prior to that, he held roles of increasing responsibility within BMS. Fouad has served as a member of the board of directors of Aprea Therapeutics Inc. since June 2020. He holds an M.D. from the University of Annaba Medical School in Algeria, and a Pediatrics degree from Université Rene Descartes in Paris, France. In addition, he received a Pediatric Oncology and Hematology degree and an M.S. in clinical and experimental pharmacology from Université Paris-Sud in France.

 

Opdivo® and Yervoy® are registered trademarks of Bristol-Myers Squibb Company.

10

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.

Curve Graphic

Christina Rossi

Chief Operating Officer

Christina Rossi
Chief Operating Officer

Christy has more than 20 years of global pharmaceutical and biotechnology experience. Since April 2022, Christy has served as Chief Operating Officer of Blueprint Medicines. Previously, she served as Chief Commercial Officer from October 2018 to April 2022 and has overseen the commercial launches of AYVAKIT® (avapritinib) and GAVRETO® (pralsetinib) across multiple indications and geographies, including the creation of commercial infrastructure and successful market access efforts in the U.S. and Europe. Prior to joining Blueprint Medicines, she served as the Multiple Sclerosis (MS) Business Unit Head, North America, at Sanofi Genzyme. In this role, she oversaw all aspects of the financial performance of Sanofi Genzyme’s MS franchise and increased market share for existing products, led the launch of new therapies and optimized operations to accelerate patient access. Previously, Christy served as Vice President, MS Sales, and Vice President, MS Patient and Provider Services, at Sanofi Genzyme. Prior to joining Sanofi Genzyme, she held various roles at Biogen Inc., including Head, Commercial Strategy for Eidetica Biopharma GmbH, Biogen’s biosimilar-focused venture, and U.S. Brand Leader for TYSABRI® (natalizumab). In addition, she consulted in the healthcare practice at the Boston Consulting Group. Christy holds a B.S. in biology, cum laude, from Duke University and an M.B.A. from Harvard Business School. She currently serves as an independent director on the board of Xilio Therapeutics and is a member of the compensation committee.

11

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.